Impact of state vaccine financing policy on uptake of heptavalent pneumococcal conjugate vaccine

American Journal of Public Health

Volumn 96, Issue 7, 2006, Pages 1308-1313

  Stokley, Shannon ^a   Shaw, Kate M ^b   Barker, Lawrence ^b   Santoli, Jeanne M ^b   Shefer, Abigail ^b  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

CHILD; DRUG COST; DRUG USE; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; LOGISTIC REGRESSION ANALYSIS; PREVENTIVE HEALTH SERVICE; REVIEW; STREPTOCOCCUS INFECTION; UNITED STATES; VACCINATION;

CHILD HEALTH SERVICES; CHILD, PRESCHOOL; ELIGIBILITY DETERMINATION; FINANCING, GOVERNMENT; HEALTH CARE SURVEYS; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MULTIVARIATE ANALYSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PUBLIC HEALTH ADMINISTRATION; STATE GOVERNMENT; UNITED STATES; UNIVERSAL COVERAGE; VACCINES, CONJUGATE;

EID: 33745655801     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2004.057810     Document Type: Review

References (37)

1. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-9):1-35.
2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
3. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-815.
4. Flannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004;291:2197-2203.
5. Ramani RR, Hall WN, Boulton M, Johnson DR, Zhu BP. Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study. Am J Public Health. 2004;94:958-959.
6. Schaffer SJ, Szilagyi PG, Shone LP, et al. Physician perspectives regarding pneumococcal conjugate vaccine. Pediatrics. 2002;110:e68.
7. Davis MM, Ndiaye SM, Freed GL, Clark SJ. One-year uptake of pneumococcal conjugate vaccine: a national survey of family physicians and pediatricians. J Am Board Fam Pract. 2003;16:363-371.
8. Freed GL, Bordley WC, dark SJ, Konrad TR. Universal hepatitis B immunization of infants: reactions of pediatricians and family physicians over time. Pediatrics. 1994;93:747-751.
9. Centers for Disease Control and Prevention. CDC vaccine price list Available at: http://www.cdc.gov/nip/vfc/cdc_vac_price_list.htm. Accessed April 2, 2006.
10. Davis MM, Ndiaye SM, Freed GL, Kim CS, Clark SJ. Influence of insurance status and vaccine cost on physicians' administration of pneumococcal conjugate vaccine. Pediatrics. 2003;112:521-526.
11. Centers for Disease Control and Prevention. Notice to readers: decreased availability of pneumococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep. 2001;50:783-784.
12. Petkus D. Wyeth experiencing temporary interruption in Prevnar shipments [press release]. Wyeth Pharmaceuticals; November 6, 2003. Available at: http://www.wyeth.com/news/Pressed_and_Released/pr11_06_2003_09_28_11.asp. Accessed April 2, 2006.
13. Centers for Disease Control and Prevention. Notice to readers: updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage-Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2001;50:1140-1142.
14. Centers for Disease Control and Prevention. Notice to readers: limited supply of pneumococcal conjugate vaccine: suspension of recommendation for fourth dose. MMWR Morb Mortal Wkly Rep. 2004;53:108-109.
15. Centers for Disease Control and Prevention. Notice to readers: updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb Mortal Wkly Rep. 2004;53:177-178.
16. Freed GL, Davis MM, Clark SJ. Variation in public and private supply of pneumococcal conjugate vaccine during a shortage. JAMA. 2003;289:575-578.
17. Stokley S, Santoli JM, Willis B, Kelley V, Vargas-Rosales A, Rodewald LE. Impact of vaccine shortages on immunization programs and providers. Am J Prev Med. 2004;26:15-21.
18. Smith PJ, Battaglia MP, Huggins VJ, et al. Overview of the sampling design and statistical methods used in the National Immunization Survey. Am J Prev Med. 2001;20(4 suppl 1):17-24.
19. Smith PJ, Simpson D, Battaglia MP, et al. Split sampling design for topical modules in the National Immunization Survey. In: Proceedings of the Survey Research Method Section. Alexandria, Va: American Statistical Association; 2000:653-658.
20. Zell ER, Ezzati-Rice T, Battaglia MP. National Immunization Survey: the methodology of a vaccination surveillance system. Public Health Rep. 2000;115:65-77.
21. Smith PJ, Hoaglin DC, Battaglia MP, Khare M, Barker LE; Centers for Disease Control and Prevention. Statistical methodology of the National Immunization Survey, 1994-2002. National Center for Health Statistics. Vital Health Stat 2. 2005;138:1-55.
22. Centers for Disease Control and Prevention. Vaccines for Children vaccine supply policy public Available at: http//www.cdc.gov/nip/vfc/st_immz_proj/data/ vacc_supply_public_2002.htm. Accessed April 2, 2006.
23. Stokley S, Smith PJ, Klevens RM, Battaglia MP. Vaccination status of children living in rural areas in the United States: are they protected? Am J Prev Med. 2001;20(4 suppl 1):55-60.
24. Cochi SL. National Immunization Program overview: celebrating our successes and looking to the future. Paper presented at: 2004 National Immunization Conference; May 11, 2004; Nashville, Tenn.
25. Orenstein WA, Atkinson W, Mason D, Bernier RH. Barriers to vaccinating preschool children. J Health Care Poor Underserved. 1990;1:315-330.
26. Cutts FT, Orenstein WA, Bernier RH. Causes of low preschool immunization coverage in the United States. Am Rev Public Health. 1992;13:385-398.
27. Bates AS, Fitzgerald JF, Dittus RS, Wolinsky FD. Risk factors for underimmunization in poor urban infants. JAMA. 1994;272:1105-1110.
28. Klevens RM, Luman ET. US children living in and near poverty: risk of vaccine-preventable diseases. Am J Prev Med. 2001;20(4 suppl 1):41-46.
29. Luman ET, McCauley MM, Shefer A, Chu SY. Maternal characteristics associated with vaccination of young children. Pediatrics. 2003;111:1215-1218.
30. Chu SY, Barker LE, Smith PJ. Racial/ethnic disparities in preschool immunizations: United States, 1996-2001. Am J Public Health. 2004;94:973-977.
31. Schaffer SJ, Bruno S. Varicella immunization practices and the factors that influence them. Arch Pediatr Adolesc Med. 1999;153:357-362.
32. Freeman VA, Freed GL. Parental knowledge, attitudes, and demand regarding a vaccine to prevent varicella. Am J Prev Med. 1999;17:153-155.
33. Taylor JA, Newman RD. Parental attitudes toward varicella vaccination. The Puget Sound Pediatric Research Network. Arch Pediatr Adolesc Med. 2000;154:302-306.
34. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months-United States, January-December 1995. MMWR Morb Mortal Wkly Rep. 1997;46:176-182.
35. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months-United States, 2000. MMWR Morb Mortal Wkly Rep. 2001;50:637-641.
36. Institute of Medicine. Calling the Shots: Immunization Finance Policies and Practices. Washington, DC: The National Academies Press; 2000.
37. Davis MM, Zimmerman JL, Wheeler JR, Freed GL. Childhood vaccine purchase costs in the public sector: past trends, future expectations. Am J Public Health. 2002;92:1982-1987.